Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Organisation › Details

Oblique Therapeutics AB (publ)

AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. *

 

Period Start 2023-11-28 existent
Products Industry therapeutic antibody
  Industry 2 AbiProt® methodology
Persons Person Nordstedt, Christer (Oblique Therapeutics 202311 CEO before Vivesto)
  Person 2 Jonasson, Mats (Oblique Therapeutics 202312 CFO)
     
Region Region Göteborg (Gothenburg)
  Country Sweden
  Street 20 Arvid Wallgrens Backe
  City 41346 Göteborg
    Address record changed: 2023-12-03
     
Basic data Employees n. a.
     
    �About Section� taken from web site of organisation on 01.12.
     
   
Record changed: 2024-02-12

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Oblique Therapeutics AB (publ)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x300px




» top